Rocket Pharmaceuticals Stock Analysis

RCKT Stock  USD 3.04  0.30  8.98%   
Rocket Pharmaceuticals is undervalued with Real Value of 12.65 and Target Price of 41.6. The main objective of Rocket Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Rocket Pharmaceuticals is worth, separate from its market price. There are two main types of Rocket Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Rocket Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Rocket Pharmaceuticals is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Rocket Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.

Rocket Stock Analysis Notes

About 93.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rocket Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 2.63. The firm last dividend was issued on the 5th of January 2018. Rocket Pharmaceuticals had 1:4 split on the 5th of January 2018. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. Rocket Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people. To find out more about Rocket Pharmaceuticals contact Gaurav MD at 609 659 8001 or learn more at https://www.rocketpharma.com.

Rocket Pharmaceuticals Investment Alerts

Rocket Pharmaceuticals generated a negative expected return over the last 90 days
Rocket Pharmaceuticals has high historical volatility and very poor performance
Net Loss for the year was (258.75 M) with profit before overhead, payroll, taxes, and interest of 0.
Rocket Pharmaceuticals currently holds about 321.37 M in cash with (209.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Rocket Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 93.0% of the company shares are owned by institutional investors
Latest headline from gurufocus.com: Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi Korsinsky ...

Rocket Pharmaceuticals Upcoming and Recent Events

26th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Rocket Largest EPS Surprises

Earnings surprises can significantly impact Rocket Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-08-08
2018-06-30-0.36-0.4-0.0411 
2020-08-05
2020-06-30-0.51-0.450.0611 
2020-11-04
2020-09-30-0.46-0.53-0.0715 
View All Earnings Estimates

Rocket Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Rocket Pharmaceuticals' ESG score is a quantitative measure that evaluates Rocket Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Rocket Pharmaceuticals' operations that may have significant financial implications and affect Rocket Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Rocket Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2025-03-31
M
Mpm Oncology Impact Management Lp2025-03-31
1.6 M
Citadel Advisors Llc2025-03-31
1.5 M
Prosight Management, Lp2025-03-31
1.5 M
Pictet Asset Manangement Sa2025-03-31
1.3 M
The Toronto-dominion Bank2025-03-31
1.1 M
Novo A/s2025-03-31
1.1 M
Baker Bros Advisors Lp2025-03-31
1.1 M
Goldman Sachs Group Inc2025-03-31
995.7 K
Rtw Investments, Llc2025-03-31
17.7 M
Wellington Management Company Llp2025-03-31
12.6 M
Note, although Rocket Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Rocket Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 327.52 M.

Rocket Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.56)(0.59)
Return On Capital Employed(0.56)(0.59)
Return On Assets(0.49)(0.51)
Return On Equity(0.56)(0.59)

Management Efficiency

Rocket Pharmaceuticals has return on total asset (ROA) of (0.348) % which means that it has lost $0.348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6045) %, meaning that it created substantial loss on money invested by shareholders. Rocket Pharmaceuticals' management efficiency ratios could be used to measure how well Rocket Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.59 in 2025. Return On Capital Employed is likely to drop to -0.59 in 2025. At this time, Rocket Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 11.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 20.6 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 4.89  5.13 
Tangible Book Value Per Share 4.21  4.42 
Enterprise Value Over EBITDA(3.86)(4.05)
Price Book Value Ratio 2.57  1.67 
Enterprise Value Multiple(3.86)(4.05)
Price Fair Value 2.57  1.67 
Enterprise Value1.1 B845.7 M
Understanding the management dynamics of Rocket Pharmaceuticals allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Beta
0.675
Return On Assets
(0.35)
Return On Equity
(0.60)

Technical Drivers

As of the 19th of July, Rocket Pharmaceuticals holds the Risk Adjusted Performance of (0.02), coefficient of variation of (3,680), and Variance of 99.26. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rocket Pharmaceuticals, as well as the relationship between them.

Rocket Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Rocket Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Rocket Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Rocket Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rocket Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rocket Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rocket Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Militello John over two months ago
Disposition of 718 shares by Militello John of Rocket Pharmaceuticals at 7.158 subject to Rule 16b-3
 
Sarbani Chaudhuri over three months ago
Insider Trading
 
Boess Carsten over three months ago
Acquisition by Boess Carsten of 23944 shares of Rocket Pharmaceuticals at 22.86 subject to Rule 16b-3
 
Aaron Ondrey over three months ago
Disposition of 7489 shares by Aaron Ondrey of Rocket Pharmaceuticals at 5.294 subject to Rule 16b-3
 
Shah Gaurav over three months ago
Acquisition by Shah Gaurav of 81655 shares of Rocket Pharmaceuticals subject to Rule 16b-3
 
Jonathan Schwartz over three months ago
Disposition of 6532 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 10.58 subject to Rule 16b-3
 
Shah Gaurav over three months ago
Disposition of 16303 shares by Shah Gaurav of Rocket Pharmaceuticals at 10.58 subject to Rule 16b-3
 
Jonathan Schwartz over three months ago
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3
 
Militello John over three months ago
Acquisition by Militello John of 20080 shares of Rocket Pharmaceuticals subject to Rule 16b-3
 
Militello John over three months ago
Acquisition by Militello John of 29920 shares of Rocket Pharmaceuticals at 9.88 subject to Rule 16b-3
 
Jonathan Schwartz over three months ago
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3
 
Jonathan Schwartz over three months ago
Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3

Rocket Pharmaceuticals Outstanding Bonds

Rocket Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rocket Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rocket bonds can be classified according to their maturity, which is the date when Rocket Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Rocket Pharmaceuticals Predictive Daily Indicators

Rocket Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rocket Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Rocket Pharmaceuticals Forecast Models

Rocket Pharmaceuticals' time-series forecasting models are one of many Rocket Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rocket Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Rocket Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Rocket Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rocket shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rocket Pharmaceuticals. By using and applying Rocket Stock analysis, traders can create a robust methodology for identifying Rocket entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Rocket Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rocket analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rocket analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
41.6Strong Buy18Odds
Rocket Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Rocket analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Rocket stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Rocket Pharmaceuticals, talking to its executives and customers, or listening to Rocket conference calls.
Rocket Analyst Advice Details

Rocket Stock Analysis Indicators

Rocket Pharmaceuticals stock analysis indicators help investors evaluate how Rocket Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rocket Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rocket Pharmaceuticals stock analysis, traders can identify Rocket Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow57.3 M
Common Stock Shares Outstanding94.8 M
Total Stockholder Equity463.2 M
Total Cashflows From Investing Activities131.7 M
Property Plant And Equipment Net83.3 M
Cash And Short Term Investments372.3 M
Cash163.6 M
Net Debt-138.1 M
50 Day M A3.8258
Total Current Liabilities40.7 M
Non Current Assets Total149.5 M
Non Currrent Assets Other1.9 M
Stock Based Compensation43.9 M

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.